538 studies on GIP agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
A favorable drug-drug interaction profile is a critical factor for the successful development of any new medication, particularly for chronic conditions like obesity where patients often take multiple concomitant drug…
This Phase 3b trial is pivotal for optimizing Retatrutide's clinical utility by identifying the most effective and well-tolerated dosing strategies for long-term use. Understanding the nuances of dose escalation can s…
If Retatrutide demonstrates a positive impact on renal function, it could represent a significant advancement in treating complex metabolic and renal diseases. As a triple GIP/GLP-1/glucagon receptor agonist, Retatrut…
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, showing promise in weight loss and glucose control in earlier studies. If this Phase 1 trial demonstrates a significant positive impa…
Understanding how kidney function affects LY3437943's pharmacokinetics is crucial for ensuring patient safety and guiding appropriate dosing strategies across diverse populations. This data is essential for developing…
This head-to-head Phase 3 trial is critically important because it directly compares retatrutide, a potential best-in-class GLP-1/GIP/Glucagon receptor triple-agonist, against semaglutide, a leading GLP-1 receptor ago…
If successful, this Phase 3b trial could establish Retatrutide as a highly effective and safe treatment option for obesity and overweight, potentially offering superior weight loss outcomes compared to existing therap…
Preventing muscle loss during significant weight reduction is critical for long-term health outcomes, as preserved muscle mass contributes to better metabolic function, strength, and overall quality of life. If succes…
This landmark study provides strong evidence that current recommendations for discontinuing GLP-1/GIP agonists before upper endoscopy may be overly cautious. The findings suggest that patients can safely continue thei…
This research provides crucial evidence that GLP-1 medicines offer a superior weight loss profile by effectively reducing fat mass while preserving vital muscle mass and function. This finding is particularly signific…
This research highlights a crucial, often overlooked, aesthetic side effect of rapid weight loss induced by GLP-1 RAs, which can significantly impact patient satisfaction and body image. Understanding this phenomenon …
This study highlights a critical emerging trend in plastic surgery, demonstrating how advancements in pharmacotherapy for weight loss directly influence the demand for body contouring procedures. Understanding this sh…
This study provides crucial real-world data on the prevalence of hair shedding among GLP-1 RA users, definitively identifying rapid weight loss as a key contributing factor. Understanding this common side effect can h…
The study aimed to demonstrate that adding testosterone undecanoate could significantly enhance the therapeutic benefits for late responders to tirzepatide. While specific quantitative data is not available in the pro…
The development of these incretin-based medications marks a paradigm shift in obesity treatment, offering pharmacological options with efficacy levels previously only achievable through bariatric surgery. This advance…
This case report is crucial as it underscores the importance of careful and gradual insulin management when initiating potent glucose-lowering agents like tirzepatide. While tirzepatide is highly effective for glycemi…
This meta-analysis provides compelling evidence that weight loss is a critical determinant for reversing MASLD histological damage, offering a clear and actionable therapeutic target. The findings suggest that even mo…
This study provides compelling evidence that Tirzepatide could serve as a valuable adjunct therapy for overweight or obese individuals with Type 1 Diabetes, offering benefits beyond traditional insulin management. The…
Understanding the real-world adverse event profile of Tirzepatide and Semaglutide when used adjunctively in Type 1 Diabetes is critically important for both clinicians and patients. This information can help manage ex…
This study provides crucial evidence for the comparative effectiveness of next-generation incretin therapies, offering valuable insights for clinicians. The findings suggest that Tirzepatide may be the preferred choic…
This study provides crucial evidence that optimizing the use of highly effective glucose-lowering agents can lead to substantial long-term cost savings and significantly improved patient quality of life. The findings …
This study provides crucial real-world evidence supporting the use of GLP-1 RAs in solid-organ transplant recipients, a population often excluded from pivotal trials due to complex medical profiles. The superior effic…
This robust systematic review and meta-analysis provides compelling evidence that GLP-1 receptor agonists are highly effective in achieving MASH resolution and improving liver fibrosis, addressing a major unmet medica…
These findings provide crucial evidence for healthcare policy decisions and formulary inclusions, offering a global perspective on the economic value of modern diabetes treatments. Understanding the long-term economic…
This study highlights a significant and rapid shift in GLP-1 agonist utilization patterns, extending well beyond their primary indication for type 2 diabetes into the non-diabetic population. The substantial increase …
This study provides crucial evidence that tirzepatide, a dual GIP/GLP-1 receptor agonist, offers superior cardiovascular protection compared to the established GLP-1 receptor agonist dulaglutide in patients with type …
This research provides invaluable, patient-centered insights that are crucial for optimizing the development, prescription, and long-term success of obesity pharmacotherapies. Understanding these deeply personal prefe…
This study highlights the critical challenge of maintaining weight loss after discontinuing potent anti-obesity medications like Semaglutide and Tirzepatide in a real-world clinical setting. It underscores the need fo…
This comprehensive network meta-analysis provides crucial evidence that Tirzepatide may be the most efficacious pharmacological option for weight management in individuals with obesity who do not have Type 2 Diabetes.…
This comprehensive meta-analysis solidifies the role of GLP-1 receptor agonists as highly effective pharmacological interventions for obesity management, providing strong evidence for their widespread clinical adoptio…
This study provides compelling real-world evidence that Tirzepatide, a dual GLP-1 and GIP receptor agonist, may offer superior neuroprotection compared to semaglutide (a GLP-1 receptor agonist) in patients with type 2…
This study highlights ARD-101 as a promising novel therapeutic strategy for obesity and metabolic disorders, leveraging a gut-restricted mechanism to potentially minimize systemic side effects. The synergistic effect …
This case report highlights a critical, albeit rare, adverse event associated with tirzepatide use in non-diabetic individuals seeking weight loss. It underscores the importance of clinician awareness regarding the po…
This comprehensive scoping review provides compelling evidence that GLP-1 receptor agonists and Tirzepatide are not just effective for glycemic control and weight management, but also offer substantial and consistent …
This case report highlights a critical safety concern for patients on tirzepatide and SGLT-2 inhibitors, emphasizing the importance of patient education regarding 'sick-day rules.' The finding that these agents can be…
This joint guidance statement represents a significant step forward in standardizing and optimizing the pharmacological management of overweight and obesity in the United States. By providing clear, evidence-based rec…
This comprehensive review provides crucial guidance for clinicians and patients regarding the safe and effective use of GLP-1 RAs in individuals of reproductive age. It underscores the critical need for thorough couns…
This real-world evidence strongly suggests that Tirzepatide may offer significant cardiovascular protection beyond its established metabolic benefits, even in patients without diabetes. The observed reduction in recur…
This meta-analysis provides compelling evidence that Tirzepatide, a dual GIP/GLP-1 receptor agonist, offers significant therapeutic potential for patients with HFpEF. The observed improvements in weight, glycemic cont…
This study highlights a critical concern: while GLP-1 receptor agonists are highly effective for weight loss, the potential for significant lean muscle mass loss needs careful consideration. Preserving muscle is vital…